Aim: The objective of this study is to investigate prognostic factors affecting survival of patients undergoing concurrent or sequential chemoradiotherapy (CRT) for stage III non-small-cell lung cancer (NSCL). Methods and materials: We retrospectively reviewed the clinical records of 148 patients with advanced, inoperable stage III NSCLC, who were treated between 2007 and 2015. Results: The median survival was found to be 19 months and 3-year overall survival was 27%. Age (CRT, performance status, induction/consolidation chemotherapy and presence of comorbidities did not affect survival (p>0.050). Conclusion: Young age, stage IIIA, radiotherapy dose and concurrent chemoradiotherapy may positively affect survival in stage III NSCL cases.
Urvay, S., Yucel, B., Erdis, E., & Turan, N. (2016). Prognostic Factors in Stage III Non-Small-Cell Lung Cancer Patients. Asian Pacific Journal of Cancer Prevention, 17(10), 4693-4697. doi: 10.22034/APJCP.2016.17.10.4693
MLA
Semiha Elmaci Urvay; Birsen Yucel; Eda Erdis; Nedim Turan. "Prognostic Factors in Stage III Non-Small-Cell Lung Cancer Patients". Asian Pacific Journal of Cancer Prevention, 17, 10, 2016, 4693-4697. doi: 10.22034/APJCP.2016.17.10.4693
HARVARD
Urvay, S., Yucel, B., Erdis, E., Turan, N. (2016). 'Prognostic Factors in Stage III Non-Small-Cell Lung Cancer Patients', Asian Pacific Journal of Cancer Prevention, 17(10), pp. 4693-4697. doi: 10.22034/APJCP.2016.17.10.4693
VANCOUVER
Urvay, S., Yucel, B., Erdis, E., Turan, N. Prognostic Factors in Stage III Non-Small-Cell Lung Cancer Patients. Asian Pacific Journal of Cancer Prevention, 2016; 17(10): 4693-4697. doi: 10.22034/APJCP.2016.17.10.4693
)